Crosslinked Hyaluronic Acid at 0.03%: A Low‑Dose Penetration Enhancer That Could Reframe Skincare Formulation

Table of Contents

1. Key Highlights:
2. Introduction
3. What the study demonstrated: low‑dose crosslinked HA enhances hydrophilic delivery
4. How crosslinked HA differs from conventional HA and why that matters
5. Proposed mechanism: film formation plus hydration-driven partitioning
6. Which actives are likely to benefit — and which will not
7. Analytical techniques that confirmed delivery enhancement
8. Practical formulation guidance for leveraging crosslinked HA at 0.03%
9. Safety, biocompatibility and regulatory considerations
10. Commercial implications: product positioning, claims and market differentiation
11. Limitations of the current evidence and open questions
12. Real‑world examples and hypothetical case studies
13. Steps for formulators to validate performance in house
14. Next research directions and industry implications
15. FAQ

Key Highlights:

• New research shows topical crosslinked hyaluronic acid (HA) at 0.03% acts as a biocompatible penetration enhancer for hydrophilic actives while retaining hydration and barrier-support functions.
• Enhancement was demonstrated in porcine and human skin explants using AFM and MALDI‑MSI; lipophilic actives did not show improved delivery.
• Practical opportunities include minimalist, barrier‑friendly formulations that increase bioavailability of water‑soluble actives (niacinamide, peptides, vitamin C, some tyrosinase inhibitors) without harsher chemical enhancers.

Introduction

Hyaluronic acid has long been a cornerstone of skincare for its capacity to bind water and improve skin hydration. Recent research from Colgate‑Palmolive and Aliri expands that role: a crosslinked form of HA applied at remarkably low concentrations (0.03%) can enhance topical delivery of hydrophilic actives into skin tissue. That finding repositions crosslinked HA from primarily a moisture-retention ingredient to a multifunctional delivery vehicle that supports simplified, efficacy‑driven formulations.

This article synthesizes the study’s findings, explains the likely mechanisms, compares crosslinked and linear HA behaviors, explores which actives are likely to benefit, and translates the evidence into actionable guidance for formulators, brand teams, and clinical practitioners. The analysis also reviews the analytical techniques used to demonstrate penetration enhancement, assesses safety and regulatory considerations, and outlines the next research steps that the industry needs to validate and apply this insight at scale.

What the study demonstrated: low‑dose crosslinked HA enhances hydrophilic delivery

The research published in the International Journal of Cosmetic Science reports that topically applied crosslinked HA at 0.03% increased the penetration of hydrophilic actives into both porcine and human skin explants. Key experimental takeaways:

• Enhancement was selective for hydrophilic actives; lipophilic compounds did not show increased penetration.
• Crosslinked HA maintained its hydration and protective film-forming properties while enabling greater permeation of water‑soluble molecules.
• The investigators linked the penetration effect to strong water‑binding capacity and to film formation, with atomic force microscopy (AFM) and MALDI‑MSI supporting these mechanisms.
• The ingredient increased delivery of medium‑molecular‑weight HA species, suggesting a potential to amplify the benefit of other HA fractions already present in formulations.

The reported concentration — 0.03% — is notable. It sits far below common usage levels for HA as a viscosity modifier or humectant, implying that functional delivery effects can be achieved without radical reformulation or major rheological shifts.

How crosslinked HA differs from conventional HA and why that matters

Hyaluronic acid exists in multiple forms within cosmetics: linear high‑molecular‑weight HA, low‑molecular‑weight fragments, partially hydrolyzed forms, and crosslinked or chemically modified polymers. Differences that matter for topical delivery include molecular weight, chain mobility, film‑forming behavior, and water-binding capacity.

• Molecular size: Linear high‑MW HA (often >1 MDa) typically remains at the skin surface because its size restricts penetration. Crosslinking produces a networked polymer that can present very different physical properties despite comparable overall molecular weight metrics.
• Film formation: Crosslinked HA forms robust, cohesive films with defined surface topography and mechanical behavior. Those films can influence the distribution, residency time, and microenvironment (water activity, partitioning) of co-formulated actives.
• Water binding/swelling: Crosslinked networks trap and retain water strongly. When applied to skin, they hold a water-rich microenvironment at the outermost layers, which alters partitioning behavior for water‑soluble molecules and can increase their apparent solubility at the skin surface.
• Diffusional pathways: Network architecture may change local diffusivity and transport pathways across the stratum corneum and viable epidermis, favoring hydrophilic transit routes.

Brands commonly list crosslinked forms on labels as “Sodium Hyaluronate Crosspolymer,” “Crosslinked Sodium Hyaluronate,” or similar INCI descriptions. Whereas linear HA often serves largely as a humectant or viscosity builder, crosslinked HA at low doses is positioned as a dual‑action ingredient: hydration plus delivery enhancement.

Proposed mechanism: film formation plus hydration-driven partitioning

The study attributes delivery enhancement to two intertwined properties: strong water binding and film-forming behavior. AFM and MALDI‑MSI provided complementary evidence.

• Film architecture and surface activity: AFM imaging showed that crosslinked HA forms a structured film on the skin surface. That film likely modifies microtopography and the interfacial energy between the formulation and stratum corneum, influencing how co‑formulated actives distribute and contact the skin.
• Water retention and microenvironment: Crosslinked HA retains water, creating a hydrated microenvironment that increases the local availability of hydrophilic solutes. Water‑soluble actives have improved partitioning into this microenvironment and thereby increased diffusion into the epidermis.
• Facilitation of medium‑MW HA migration: MALDI‑MSI mapping demonstrated increased presence of medium‑molecular‑weight HA species deeper in the skin when crosslinked HA was applied. This suggests the crosslinked network may also influence the movement of other polymeric species, potentially by carrying them within the hydrated film or by modifying skin hydration gradients that drive diffusion.

The enhancement is not a classical chemical disruption of lipid lamellae (as with many small‑molecule penetration enhancers). Instead, crosslinked HA appears to modulate physical transport pathways through hydration and film-mediated partitioning — a mechanism that preserves barrier integrity while improving bioavailability for compatible actives.

Which actives are likely to benefit — and which will not

The selective nature of the enhancement has practical implications. Formulators should pair crosslinked HA with appropriate actives.

Likely beneficiaries (hydrophilic or water‑soluble compounds):

• Niacinamide (vitamin B3): Widely used for brightening and barrier support; water‑soluble and commonly formulated in serums.
• Ascorbic acid and stabilized vitamin C derivatives that are water‑soluble (e.g., magnesium ascorbyl phosphate): Enhanced delivery could improve antioxidant and depigmenting activity.
• Water‑soluble peptides: Many peptides are polar and may penetrate better in a hydrated microenvironment.
• Alpha‑hydroxy acids (glycolic acid, lactic acid) and polyhydroxy acids, when present in appropriate concentrations and pH.
• Tyrosinase inhibitors that are hydrophilic (e.g., tranexamic acid, kojic acid in certain formulations) — relevant for hyperpigmentation products.
• Low‑to‑medium molecular weight HA fragments present as cosolutes, where increased delivery could amplify moisturization and volumizing claims.

Unlikely or limited benefit (lipophilic or oil‑soluble actives):

• Retinoids and derivatives that are lipophilic (retinol, retinyl esters): Partitioning into lipid domains rather than the hydrated film governs their delivery.
• Oil‑soluble antioxidants and botanical lipophilic extracts: Enhanced hydration-driven partitioning does not favor these compounds.
• High‑lipophilicity sunscreens and other occlusive agents.

Strategic pairing examples:

• A brightening serum that combines 0.03% crosslinked HA with 5% niacinamide and 2% tranexamic acid to increase epidermal delivery of the hydrophilic actives.
• A peptide rejuvenation serum with 0.03% crosslinked HA as a delivery facilitator for multiple small peptides (e.g., palmitoyl tetrapeptide analogs that are relatively polar).
• A barrier‑strengthening cream where crosslinked HA aids the penetration of hydrophilic humectants and low‑MW HA to complement occlusive or emollient agents.

Clinical context matters. Actives that benefit from increased penetration may require adjusted concentrations or safety reassessment because higher delivered dose could amplify efficacy and side‑effect risk.

Analytical techniques that confirmed delivery enhancement

The research used robust analytical approaches to demonstrate and visualize increased delivery.

• Atomic Force Microscopy (AFM): AFM imaged the film formed by crosslinked HA, revealing surface morphology and mechanical properties at the nanoscale. That evidence supports the hypothesis that film formation alters the interface between product and skin.
• MALDI‑MSI (Matrix‑Assisted Laser Desorption/Ionization Mass Spectrometry Imaging): MALDI‑MSI provided spatial maps of molecular distribution within skin cross‑sections. The technique detected increased levels of medium‑molecular‑weight HA species deeper in treated explants, offering direct visual proof that crosslinked HA co‑application can alter the distribution of other polymeric or hydrophilic species.
• Ex vivo permeation in skin explants: Using porcine and human explants, the researchers quantified actives in different skin layers to show differential penetration with and without crosslinked HA.

These methods together reduce the risk of artifact. AFM demonstrates a plausible physical change at the surface; MALDI‑MSI visualizes molecular movement within tissue; and ex vivo permeation quantifies the effect. The triad of evidence strengthens the conclusion that crosslinked HA can function as a delivery enhancer for suitable actives.

Practical formulation guidance for leveraging crosslinked HA at 0.03%

Translating laboratory findings into marketable products requires attention to compatibility, stability, sensory profile, and claim substantiation. The following guidance targets formulators and product development teams.

1. Start low, test broadly

• The study shows an effect at 0.03%; use that concentration as a baseline. Titrate upward only if justified by performance testing, since higher levels may alter texture, rheology, and aesthetics.
• Conduct in vitro/ex vivo permeation studies during development to quantify the enhancement for the specific actives being used.

2. Pair with hydrophilic actives

• Design serums and water‑based matrices where actives are soluble in the continuous phase. Typical actives to test include niacinamide, stabilized vitamin C derivatives, small peptides, tranexamic acid, and low‑MW HA fractions.
• Avoid expecting benefit for lipophilic actives without additional delivery mechanisms.

3. Manage pH and stability

• Crosslinked HA formulations need pH and preservative systems compatible with both the polymer and the active actives. Many water‑soluble actives (ascorbic acid, acids) require acidic pH; ensure crosslinked HA maintains integrity in the selected pH range.
• Evaluate long‑term stability: crosslinked networks can be sensitive to hydrolysis or ionic strength changes depending on their chemistry and crosslinker.

4. Optimize sensory attributes

• At 0.03% the rheological impact will be small. However, film formation can affect skin feel. Consider pairing with light emollients (caprylic/capric triglyceride at low levels) or silicone alternatives if a smooth afterfeel is desired.
• Balance tackiness: crosslinked films sometimes increase tack if no emollients are present; consumer testing will reveal acceptability.

5. Preserve barrier-friendly claims

• One value proposition is enhancing delivery without harsh penetration enhancers. Preserve that message by avoiding co‑formulation with surfactants or solvents known to disrupt lipid lamellae.
• Perform transepidermal water loss (TEWL) and irritation tests to substantiate barrier integrity claims.

6. Adjust actives dosing and safety margins

• Enhanced penetration may increase local delivered dose. Revisit safety assessment, local tolerance, and systemic exposure models where necessary.
• For potent actives with known irritancy or systemic absorption concerns (eg, high concentration acids, certain peptides), introduce staged consumer guidance (patch testing, frequency limits) and consider lowering actives concentration if necessary.

7. Manufacturing and batch consistency

• Crosslink density and source chemistry influence performance. Work with ingredient suppliers to secure tight specifications and batch release testing.
• Monitor rheology, polymer molecular weight distribution, and residual crosslinking agents as part of quality control.

8. Packaging and delivery formats

• Moisture vapor transmission and compatibility with polymer films might affect delivery. Airless pumps and opaque bottles can preserve stability for sensitive actives.
• Consider serum and lotion bases as primary vehicles; masks and leave‑on treatments may provide prolonged contact time, potentially increasing effect.

Safety, biocompatibility and regulatory considerations

The study labels crosslinked HA as biocompatible at the tested concentration. For market development, the following considerations apply:

• Local irritation and sensitization: Although HA is generally well tolerated, crosslinked chemistries may introduce residual crosslinkers or modifiers. Conduct standard battery testing (in vitro and human repeat insult patch testing) to exclude irritation or sensitization.
• Systemic exposure: Low concentration and topical application suggest minimal systemic absorption risk, but actives whose delivery is enhanced should be reassessed for systemic safety if they have known systemic effects.
• Claim substantiation: Claims such as “enhanced delivery” or “boosts efficacy” should be backed by measurable endpoints — in vitro/ex vivo penetration data alone may support mechanistic claims, but human efficacy studies are usually required for stronger marketing claims (e.g., visible reduction in hyperpigmentation over X weeks).
• INCI and labeling: Use the ingredient’s INCI name (commonly “Sodium Hyaluronate Crosspolymer” or similar) and disclose any relevant modifiers. If the crosslinking chemistry uses specific crosslinkers that leave residues, regulatory authorities in some jurisdictions require disclosure or limits.
• Claims around barrier integrity: If promoting “barrier-friendly” formulations, document TEWL, corneometry (hydration), and clinical safety to support that claim.

Commercial implications: product positioning, claims and market differentiation

This research offers several go‑to-market opportunities.

• Minimalist, performance-focused serums: Brands can claim hydration plus enhanced delivery of key actives using a single multifunctional ingredient, reducing ingredient counts and simplifying labels—appealing to consumers seeking streamlined routines.
• Dermocosmetic positioning: For clinically oriented lines, crosslinked HA can be paired with hydrophilic actives aimed at hyperpigmentation or mild anti‑ageing, strengthening efficacy claims without aggressive chemical enhancers.
• Differentiation through science: Visualized penetration (MALDI‑MSI) and nanoscale film evidence (AFM) make compelling claims in technical literature and regulatory dossiers. Brands with clinical budgets can translate these into consumer‑facing claims by running randomized controlled trials showing superior clinical endpoints.
• Hybrid systems: Combine crosslinked HA in a two‑step system where an initial delivery serum primes the skin for an active mask or patch, leveraging increased epidermal availability for short‑term, high‑impact treatments.

Be cautious when wording marketing claims. “Enhances penetration” must be qualified (eg, “enhances delivery of water‑soluble actives while supporting skin hydration”) and supported by product‑specific data.

Limitations of the current evidence and open questions

The study provides strong early evidence, but important gaps remain:

• Ex vivo vs in vivo translation: Results in porcine and human skin explants are encouraging, but in vivo human trials are required to confirm clinical efficacy and tolerability across skin types, ages, and conditions.
• Long‑term effects on barrier: Repeated use could have different outcomes than single application. Longitudinal studies should track TEWL, barrier recovery, and microbiome changes.
• Crosslink chemistry variability: Not all crosslinked HA products are identical. Crosslink density, crosslinker type, and manufacturing processes could alter performance. Comparative studies across suppliers are needed.
• Effect on a wider set of actives: The study identified hydrophilic vs lipophilic patterns, but the active universe is broad. Systematic screening of common cosmetic actives (vitamin derivatives, peptides, inhibitors) will clarify practical pairing rules.
• Dose–response and vehicle interactions: While 0.03% produced measurable effects, the dose–response relationship and interaction with different vehicle types (gels, creams, emulsions) require mapping.
• Mechanistic granularity: Film formation and hydration are plausible drivers, but biophysical studies (e.g., diffusion coefficients in hydrated films) and modeling of transport kinetics will refine our mechanistic understanding.

Addressing these unknowns will determine how widely crosslinked HA can be deployed as a delivery platform.

Real‑world examples and hypothetical case studies

Illustrative examples demonstrate how crosslinked HA could be used in practice.

Case study 1 — Brightening serum (market application)

• Product idea: A lightweight morning serum targeting hyperpigmentation that pairs tranexamic acid (5%), niacinamide (4%), stabilized vitamin C derivative (3%), and crosslinked HA at 0.03%.
• Rationale: Tranexamic acid and niacinamide are hydrophilic; crosslinked HA increases their epidermal access, potentially improving reduction of melanin synthesis without relying on stronger exfoliants or high acid concentrations.
• Development steps: Conduct ex vivo permeation, followed by a 12‑week randomized clinical trial measuring melanin index and spot size reduction versus an identical formula without crosslinked HA.

Case study 2 — Anti‑ageing peptide complex

• Product idea: A night serum containing multiple water‑soluble peptides known for collagen stimulation paired with 0.03% crosslinked HA.
• Rationale: Peptides can be limited by penetration. The hydrated film could increase peptide residency and flux to the viable epidermis, enhancing signaling.
• Development steps: Use ex vivo skin explants and gene expression profiling to measure collagen and matrix protein markers after treatment; follow with a consumer study measuring fine line depth and skin firmness.

Case study 3 — Minimalist barrier repair cream

• Product idea: A short ingredient‑list moisturizer that relies on crosslinked HA for hydration and enhanced delivery of low‑dose panthenol and niacinamide for barrier repair.
• Rationale: Crosslinked HA provides hydration, film formation and deeper delivery of water‑soluble actives, allowing for a shorter INCI list and potentially fewer irritants for sensitive skin.
• Development steps: Conduct TEWL and corneometry tests to verify barrier improvement and hydration over 4–8 weeks.

These examples show how crosslinked HA can be a differentiator in clinical and consumer segments when the science is translated into product development pathways.

Steps for formulators to validate performance in house

Build a validation pipeline before committing to production:

1. Bench chemistry

• Confirm solubility and stability of crosslinked HA at the target pH and with co‑actives.
• Assess rheology and sensory outcomes in prototype bases.

2. Analytical and ex vivo testing

• Ex vivo permeation assays using porcine or human skin explants to quantify delivery differences.
• AFM imaging to observe film formation where resources allow.
• MALDI‑MSI or LC‑MS techniques to visualize and quantify active distribution.

3. Safety and tolerance testing

• In vitro cytotoxicity and irritation panels (reconstructed epidermis tests).
• Human repeat insult patch tests and 48‑hour patch tests for initial tolerance data.

4. Human efficacy trials

• Short proof‑of‑concept trials with objective endpoints (TEWL, melanin index, wrinkle topography) and a placebo or comparator arm without crosslinked HA.
• Consumer acceptability studies for finish, scent, and tactile properties.

5. Regulatory review and claims substantiation

• Ensure label accuracy and regulatory compliance for the intended markets.
• Prepare a claims support dossier combining mechanistic, ex vivo, and clinical evidence.

Next research directions and industry implications

The discovery that low‑dose crosslinked HA can enhance hydrophilic delivery invites deeper investigation and broader product innovation.

Priority research questions:

• Which specific crosslinking chemistries and densities optimize delivery while maintaining biocompatibility and desirable sensorial properties?
• How does crosslinked HA interact with skin microbiome, and does the hydrated film alter microbial communities over time?
• Can controlled release be engineered through crosslinking strategies to provide sustained active delivery?
• Are there synergistic combinations with mild physical methods (microneedling, controlled occlusion) that remain safe and effective?

Industry implications:

• Ingredient suppliers may commercialize tailored crosslinked HA grades optimized for delivery performance across specific actives.
• Regulatory and testing frameworks might evolve to include delivery‑enhancing polymers in claims substantiation pathways.
• Brands able to integrate robust clinical evidence will differentiate in a crowded market where measurable efficacy increasingly determines consumer choice.

FAQ

Q: What exactly is crosslinked hyaluronic acid? A: Crosslinked HA is hyaluronic acid whose polymer chains have been chemically linked together to form a network. This changes its physical properties — often increasing film formation, water retention, and mechanical stability — compared with linear HA.

Q: How much crosslinked HA is needed to boost penetration? A: The study demonstrated enhancement at 0.03% applied topically. That low level can be effective without significantly altering product rheology, though formulators should validate dose‑response for each active and vehicle.

Q: Will crosslinked HA make the skin barrier worse by increasing penetration? A: The reported mechanism is not classical lipid disruption. Crosslinked HA appears to enhance delivery through hydration and film-mediated partitioning rather than chemically disturbing the lipid matrix. Nonetheless, products should be tested for TEWL and irritation to confirm barrier friendliness under expected use conditions.

Q: Which actives should be paired with crosslinked HA? A: Water‑soluble, hydrophilic actives are the best candidates: niacinamide, certain vitamin C derivatives, tranexamic acid, many peptides, and some low‑MW HA fragments. Lipophilic ingredients like retinoids and oil‑soluble antioxidants are unlikely to benefit.

Q: Does crosslinked HA work in all product types? A: It is most compatible with water‑based serums, gels and creams where hydrophilic actives are present in the continuous phase. Emulsion vehicles can work if the active is in the aqueous phase and the crosslinked HA remains functional in the chosen pH and ionic conditions.

Q: Are there safety concerns with crosslinked HA? A: HA is generally biocompatible, but variations in crosslinking chemistry can introduce residues or change behavior. Conduct standard safety testing (irritation, sensitization) and reassess actives’ safety margins if penetration is enhanced.

Q: Can crosslinked HA replace other penetration enhancers? A: For hydrophilic actives, crosslinked HA offers a milder alternative to surfactants or solvents that disrupt lipids. It does not replace enhancers targeted to lipophilic actives. Choice of enhancer should be guided by active properties and product goals.

Q: How should brands substantiate claims about enhanced delivery? A: Combine mechanistic ex vivo data (permeation assays, imaging) with clinical endpoints in human trials. Transparent claim language and data-backed substantiation strengthen regulatory and consumer trust.

Q: What are the next steps for a formulator interested in using crosslinked HA? A: Source a controlled, well‑characterized grade from a reputable supplier, make a prototype at 0.03% in a compatible vehicle, and run ex vivo permeation and basic safety tests. Progress to clinical testing if performance objectives are met.

Q: Where can I read the original research? A: The study is published in the International Journal of Cosmetic Science; consult the journal for the full paper and methodological details.

This evidence positions crosslinked HA as more than a hydrator: at low concentrations it can act as a delivery facilitator for hydrophilic actives, enabling simplified formulations that maintain barrier integrity. The path forward requires careful formulation, rigorous validation, and clinical translation to realize commercial products that are both differentiated and demonstrably effective.